Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

减肥药物赛道的竞争异常激烈，但华尔街对一家名为Viking Therapeutics（NASDAQ: ...

We recently published a list of Jim Cramer’s Thoughts on These 7 Stocks. In this article, we are going to take a look at ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $33.69, moving +0.78% from the previous trading session.

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

Since VKTX is devoid of marketed drugs, investors will focus on pipeline updates when it reports Q4 results next week.

Viking Therapeutics (NASDAQ:VKTX – Get Free Report) is expected to release its earnings data after the market closes on ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...

其他开发GLP-1药物的公司包括阿斯利康（AZN.US）、安进（AMGN.US）、辉瑞（PFE.US）、罗氏、Altimmune （ALT.US）、Viking Therapeutics （VKTX.US）、Zealand 、Terns Pharmaceuticals （TERN.US）和Structure Therapeutics （GPCR.US）。

智通财经获悉，周四，Allurion ...